ESMO 2025: Highlights and analysis
ESMO 2025: Highlights and analysis
ctDNA-guided adjuvant chemo de-escalation reduces toxicity with comparable outcomes in stage III colon cancer
Trastuzumab deruxtecan demonstrates advance in treatment for HER2-positive gastric cancer
Zanzalintinib plus atezolizumab improves survival in refractory mCRC
Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2-negative GC/GEJC/EAC
Durvalumab combined with FLOT improves survival in resectable gastric and GEJ adenocarcinoma
MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection
Circulating tumour DNA a useful marker in CRC treatment efficacy, but only alongside others
ctDNA testing improves detection of treatable metastases compared to standard care in colorectal cancer
Phase I/II trial shows promising activity of invikafusp alfa in PD-1–resistant GI cancers
Nivolumab plus ipilimumab improves survival results in MSI-H/dMMR metastatic colorectal cancer
Encorafenib, cetuximab plus chemotherapy yields good response in BRAF V600E mCRC